Nitrofurantoïne Prolepha (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA, ribosomal proteins, and cell‑wall precursors. This multi‑target attack interferes with carbohydrate metabolism and cell‑wall synthesis, resulting in bactericidal activity primarily within the urinary tract.

The dosage of Nitrofurantoïne Prolepha is determined by the prescribing clinician based on the infection severity, patient renal function, and local guidelines. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Nitrofurantoïne is classified as pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the risk. Limited data are available for breastfeeding; a prescriber should evaluate the risk‑benefit balance.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nitrofurantoin is distinct from fluoroquinolones and trimethoprim‑sulfamethoxazole because it achieves high concentrations in urine and has a narrow spectrum focused on common uropathogens. It is often preferred for uncomplicated cystitis when resistance to other agents is a concern, but it requires adequate renal function for efficacy.

Store the product at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, excessive heat, and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Nitrofurantoïne Prolepha is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The exact dosing schedule should be followed as prescribed by the healthcare professional.

Serious risks include pulmonary toxicity (interstitial lung disease or acute respiratory distress), hepatic injury, severe allergic reactions such as Stevens‑Johnson syndrome, and hemolytic anemia in patients with G6PD deficiency. Patients should seek immediate medical attention if they experience shortness of breath, jaundice, rash, or dark urine.

Nitrofurantoïne Prolepha is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min), known hypersensitivity to nitrofurantoin, or a history of G6PD deficiency. It should also be avoided in late‑term pregnancy (≥ 38 weeks) due to potential fetal hemolysis.